Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Primary Ciliary Dyskinesia (PCD) Market Forecast: What Value Will The Market Reach By 2030?
The primary ciliary dyskinesia (pcd) market size has shown robust growth recently. It will grow from $0.49 billion in 2025 to $0.53 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. This historic growth can be ascribed to several factors, including insufficient awareness of pcd, a lack of consistent diagnostic methods, reliance on standard antibiotic treatments, limited access to specialized clinics, and low uptake of airway clearance devices.
The primary ciliary dyskinesia (pcd) market is anticipated to show significant expansion over the next few years. It is expected to reach $0.68 billion in 2030, with a compound annual growth rate (CAGR) of 6.6%. This projected growth can be attributed to the development of gene therapy and stem cell interventions, increasing investments in diagnostic laboratories, a rising prevalence of rare respiratory disorders, the adoption of personalized medicine approaches, and the integration of digital health and remote monitoring solutions. Key trends during the forecast period include the increasing uptake of genetic testing for early diagnosis, a rising utilization of advanced imaging techniques for monitoring, the expansion of airway clearance therapy devices, a growing demand for personalized antibiotic treatments, and a focus on innovative therapies such as gene and stem cell therapy.
Get A Free Sample Report With In-Depth Market Insights:
Primary Ciliary Dyskinesia (PCD) Market Growth Momentum: What Factors Are Shaping Demand?
An anticipated surge in the demand for gene therapy is projected to stimulate the expansion of the primary ciliary dyskinesia market moving ahead. Gene therapy is a medical approach that modifies or replaces faulty genes within a patient’s cells to address or prevent diseases. The growing need for gene therapy is attributed to advancements in genetic research, enabling more precise treatments that identify and correct genetic disorders at a molecular level, thereby improving patient outcomes. Researchers are developing gene therapy for Primary Ciliary Dyskinesia (PCD) to rectify the genetic mutations responsible for improper cilia function in the respiratory system. This treatment works by introducing healthy genes to re-establish normal ciliary movement, enhance mucus clearance, and minimize respiratory infections. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, the first quarter of 2023 saw 247 gene therapy programs in Phase II clinical trials, a number which increased by 5%, reaching a total of 260 ongoing Phase II gene therapy trials by the end of the second quarter. Therefore, the escalating demand for gene therapy is a key factor propelling the growth of the primary ciliary dyskinesia market.
Primary Ciliary Dyskinesia (PCD) Market Segment Landscape: Which Areas Lead Development?
The primary ciliary dyskinesia (pcd) market covered in this report is segmented –
1) By Treatment: Antibiotics, Airway Clearance Therapies, Surgical Interventions, Other Treatments
2) By Method: Genetic Testing, Imaging Techniques, Clinical Evaluation, Lung Function Tests
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Retail Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Antibiotics: Macrolides, Penicillins, Cephalosporins, Fluoroquinolones, Aminoglycosides
2) By Airway Clearance Therapies: Chest Physiotherapy, High-Frequency Chest Wall Oscillation (HFCWO), Positive Expiratory Pressure (PEP) Therapy, Intrapulmonary Percussive Ventilation (IPV), Oscillatory Positive Expiratory Pressure (OPEP)
3) By Surgical Interventions: Sinus Surgery, Tympanostomy Tube Placement, Lung Transplantation
4) By Other Treatments: Mucolytics, Immunomodulatory Therapies, Gene Therapy, Stem Cell Therapy
Primary Ciliary Dyskinesia (PCD) Market Trends Redefining Industry Growth
Leading firms within the primary ciliary dyskinesia market are concentrating on creating novel solutions, notably experimental mRNA-based treatments, designed to better manage symptoms and elevate the quality of life for patients. An investigational mRNA-based therapeutic is an emerging treatment that employs messenger RNA (mRNA) to instruct cells to synthesize proteins capable of treating or preventing illnesses. This advanced approach addresses conditions at their molecular foundation, facilitating personalized medical interventions. For example, in June 2024, ReCode Therapeutics, Inc., a US-based biotechnology firm, introduced RCT1100, an investigational inhaled mRNA therapy. This therapy was granted orphan drug designation by the Food and Drug Administration (FDA) for treating primary ciliary dyskinesia. RCT1100 intends to re-establish ciliary function through the direct delivery of DNAI1 mRNA to airway cells. This development addresses a significant unmet demand for the approximately 45,000 individuals affected in the U.S., given the current absence of disease-modifying treatments or cures for PCD.
Primary Ciliary Dyskinesia (PCD) Market Company Landscape And Competitive Strategy
Major companies operating in the primary ciliary dyskinesia (pcd) market are Centogene NV, Revvity Inc, Quest Diagnostics Incorporated, Nationwide Children’s Hospital, Children’s Healthcare of Atlanta, National Jewish Health, Guy’s and St Thomas’ NHS Foundation Trust, University Hospital Southampton, Vanderbilt University Medical Center, Stanford Medicine, Mayo Foundation for Medical Education and Research, UNC School of Medicine, UAB Health System, University Hospital Münster, DNA Labs India Pvt Ltd, Parion Sciences Inc, ReCode Therapeutics Inc, PCD Foundation, PCD Research Consortium, European PCD Network
View The Full Primary Ciliary Dyskinesia (PCD) Market Report:
Primary Ciliary Dyskinesia (PCD) Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the primary ciliary dyskinesia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary ciliary dyskinesia (pcd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
